108Health
108health · 2007-11-29
<< The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting
|
首 页
|
A New Vision for Medical Care >>
Tying Diseases to DNA in Thousands of Women
2007-11-29
Tag:
版权声明
:转载时请以超链接形式标明文章原始出处和作者信息及
本声明
http://108health.blogbus.com/logs/11238654.html
This article provides an interesting overview on how scientists are trying to mine genetic materials collected in large clinical trials for links to common, chronic diseases—and how researchers, government agencies, and pharmaceutical companies are joining hands to work around thorny intellectual property rights problems.
Starting from the disease and working back to the
DNA
, a team of academic, government and industry researchers hope to discover the genetic causes of breast cancer, heart disease and a host of other common disorders affecting women.
The novel collaboration, which involves Brigham and Women's Hospital in Boston, the National Institutes of Health and the biotechnology giant Amgen Inc., will analyze
DNA
collected more than a decade ago from 28,000 participants in the Women's Health Study, combing it for differences between those who have developed serious illness and those who have remained healthy. Researchers believe the results will eventually enable physicians to better predict a woman's risk for disease and to tailor more effective treatments.
The project is part of a new gold rush sweeping medical research aimed at uncovering the genetic underpinnings of common diseases using new
DNA
–reading technologies. The joint involvement of corporate, government and academic players underscores the increased interest in translating existing genetics research into practical medical knowledge. But it also raises thorny questions about how to patent and commercialize discoveries stemming from publicly funded research efforts...
Under the terms of the new project, called the Women's Health Genome Study, results describing associations between genes and diseases will be posted in a public database through the NIH and made available to any scientist interested in conducting further research. "The overwhelming primary aim is to get the vast amount of these data in the public domain as quickly as possible so they can immediately advance patient care," Dr. Ridker says.
Once in the public domain, the genetic associations can't be patented, but scientists could use them as a springboard to research how to develop diagnostic tests and treatments that could be patented. "The purpose of this is to make a contribution to the global knowledge base," says Joseph P. Miletich, Amgen's senior vice president, research and development. "Amgen isn't looking for any rights to anything."
That reflects the view of the NIH that the basic links between genes and disease are such a fundamental discovery that patenting them should be discouraged. The NIH is developing guidelines for genome–wide association studies that are expected to emphasize that policy, but it has no firm rule against patents.
The new study "might be an interesting test case" of how academic scientists and industry should work together on such projects, says Elizabeth Nabel, director of the NIH's National Heart, Lung and Blood Institute. The NHLBI is contributing $4 million in grant support over five years to Dr. Ridker's study.
引用地址:
108Health
发表于
09:28:31
|
编辑
|
继续话题
|
转发
|
推荐
发表评论
原始快照:web.archive.org